WetLab Structure

The design of the $\MyColi$ system requires several intermediate constructions and experiments which will be explained on this page. For the results and the comments of each experiment, please see Results .

I. Search for an Efficient 2A Peptide

The 2A peptide sequence allows the post-transcriptional cleavage of 1 ARN sequence into 2 amino-acid sequences: one upstream and one downstream of p2A. This cleavage is done by ribosome skipping within the sequence of p2A. The construction of the peptidic bound between the two last amino-acids of p2A is interrupted, resulting in the termination of the translation of the upstream mRNA sequence. The ribosome can then either stop the translation of the mRNA or continue to translate the downstream sequence into a second, separated protein. The C-terminal extremity of the upstream protein is thus fused with the N-terminal extremity of p2A, and N-terminal extremity of the downstream protein is fused with the last amino-acid of p2A (a prolin).

We thus decided to separate our WetLab in two separate projects: on the first hand, we'll try to find a 2A peptide that works in $\small Escherichia$ $\small Coli$ (F2A f.e.); on the other hand, we'll build the $\MyColi$ system in $\small Saccharomyces$ $\small Cerevisiae$ using the p2A peptide (P2A f.e.). We'll use thus use two different TA Systems: ccdB-ccdA for $\small E.Coli$, and Kid-Kis for $\small S.Cerevisiae$ (respectively Toxin-Antitoxin), as explained in the Introduction page of our project's description.

II. E.Coli Chassis

A. Screening of different p2A-like sequences

In order to make an effective screening of different 2A peptides, we'll need to design a plasmid containing 2 molecular markers (the $\small Red$ $\small Fluorescent$ $\small Protein$ (RFP) and the alkaline phosphatase (phoA)) separated by a 2A peptide (RFP::p2A::phoA). After cloning this plasmid in bacteria lacking the phoA gene in their genome and after growth on chromogenic and selective XP-medium, we should be able to observe 4 types of results:

In the first three cases, p2A would not work properly: there is some problem at the translational or post-translational level (case 1.: for both proteins; case 2.: for GFP only ; case 3.: for phoA only). In the 4th case, p2A would work as expected: GFP is separated from phoA during the translation, and both proteins remain active after the separation.

However, we are only interested in the translational problem, which are linked to the peptide 2A, and not in the post-translational problems, which are linked to the molecular markers we use (RFP and phoA). We must thus design another experiment in order to eliminate the impact that the post-traditional effects could have on the screening.

B. Construction and quantification of the Mighty Coli system

If we could find 2A peptide which work within $\small E.Coli$, we could build our $\MyColi$ system into it. It would be done by PCR amplification (construction of the RFP-p2A-ccdA and ccdB inserts), homologous recombination (ligation of each insert in a vector carrying a different resistance gene), electroporation of the recombinant vectors into $\small E.Coli$, and growth on selective medium.

However, in order to have a valid experiment, we must first test the effect of the toxin (ccdB) alone on the bacteria – that is, the effect of the toxin without the antitoxin.

III. S.Cerevisiae Chassis

A. P2A peptide cleavage rate - Modelling

The modelling team needs to know the cleavage rate of p2A in order to compute the effectiveness of $\MyColi$. It will also give us quantitative expectation of the empiric measurement, which could lead to interesting axis of research if the measurement is too different from the prediction.

This will be done by the construction of a insert linking the p2A to two molecular markers: GFP and RFP (GFP::p2A::RFP). After ligation, electroporation and growth on selective medium, we will thus be able to measure by spectrophotometry the GFP/RFP ratio (1:1) as well as the production rate of both proteins, which should be a good indicator of those same data in $\MyColi$.

B. Quantification of the Mighty Coli system

The quantitative evaluation of $\MyColi$ in S.Cerevisiae will be done in the same way than with $\small E.Coli$: we'll compare the GFP production yield of a common yeast and the one of a yeast expressing the $\MyColi$ system (one plasmid containing the Kid gene, and the other containing the construction GFP::p2A::Kis).

The measurement will be done with the collaboration of F. Delvigne from the ULg.

C. Quality control of the Mighty Coli system

To evaluate the improvement in the quality of the protein production, we'll use Apol1 as protein of interest. Indeed, this protein possesses several isoforms, each of them the resulting of a mutation of the original Apol1 gene, and the concentration of each can be easily measured. We'll thus compare the relative concentrations of the isoforms of Apol1 produced by a common yeast with those of a yeast expressing the $\MyColi$ system (one plasmid containing the Kid gene, and the other containing the construction Apol1::p2A::Kis).

IV. Constructions and Biobricks Summaries

In order to complete our project, we might to build 11 recombinant plasmids (6 in $\small E.Coli$, 5 in $\small S.Cerevisiae$). Each chassis consists in an independent project, which should enable us to complete at least one of them at the end of the summer.

At the end of our project, we should have sent at least 7 biobricks, and maybe more if the screening of the different 2A peptides is positive.

Lab Protocols

Electroporation

Dyalisis (with 0,0250 µm filter) for 20 minutes of 12µl of ligation solution and 12µl of digested plasmid.

Insert the electrocompetent cell into the electroporation machine, and electroporate at 250V . All is well f there is no spark and the time constant approximates 4,6.

PCR Amplification

Miniprep: GenElute™ Plasmid Miniprep Kit

Bacterial cells are harvested via centrifugation, subjected to a modified alkaline-SDS lysis procedure and the DNA adsorbed onto silica in the presence of high salts. Contaminants are then removed by a simple wash step. Bound DNA is eluted in water or Tris-EDTA buffer.

Gel Purification: GenElute™ Gel Extraction Kit

The GenElute Gel Extraction Kit combines silica-binding technology with the convenience of a spin or vacuum column format. DNA fragments of interest are extracted from slices of an agarose gel and are bound to a silica membrane. Contaminants are removed by a simple spin or vacuum wash. The bound DNA is then eluted.

The purified DNA is suitable for a variety of downstream applications, such as automated DNA sequencing, PCR, restriction digestion, cloning, and labeling.

Column Purification: GenElute™ PCR Clean-Up Kit

The GenElute PCR Clean-Up Kit combines the advantages of silica binding with a microspin format. The DNA is bound on a silica membrane within the spin column. The bound DNA is washed and the clean, concentrated DNA is eluted in the buffer of choice. Each column can purify up to 100 μL or 10 μg of PCR amplified DNA and recover up to 95% of PCR products between 100 bp and 10 kb. More than 99% of the primers and most primer-dimers (<40 bp are removed).

PCR Cloning: Clontech™ In-Fusion HD Cloning Plus

The In-Fusion Enzyme premix fuses PCR-generated sequences and linearized vectors efficiently and precisely, utilizing a 15 bp overlap at their ends. This 15 bp overlap can be engineered by designing custom primers for amplification of the desired sequences. This method can be used to clone single or multiple fragments into a single vector without subcloning.

Bibliography